Search clinical trials for: checkpoint

Total 4889 results

Bristol-Myers Squibb

Terminated

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Psoriatic Arthritis

Argentina, France, Italy, United States, Canada, Belgium, Netherlands, Australia, Germany, South Africa, Spain, Norway
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
AstraZeneca

Completed

CP-675,206 In Patients With Advanced Melanoma

Malignant Melanoma

United States
AstraZeneca

Completed

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Melanoma

United States
AstraZeneca

Completed

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
Bristol-Myers Squibb

Completed

Abatacept With Methotrexate- Phase IIB

Rheumatoid Arthritis

Belgium, United States, Canada, Germany, United Kingdom, Australia, France, Ireland, Netherlands, Argentina, South Africa
Bristol-Myers Squibb

Completed

Study of MDX-010 in Stage IV Breast Cancer

Adenocarcinoma | Breast Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

Kidney Cancer

United States
Bristol-Myers Squibb

Completed

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Rheumatoid Arthritis

Belgium, Spain, United States, Germany, Italy, Mexico, United Kingdom, France, Czech Republic, Ireland
M.D. Anderson Cancer Center

Withdrawn

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Melanoma
Bristol-Myers Squibb

Completed

A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Active Rheumatoid Arthritis

Belgium, Netherlands, Spain, Germany, Sweden, United Kingdom
Amsterdam UMC, location VUmc
Medarex; Cell Genesys

Terminated

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Prostate Cancer

Netherlands
Bristol-Myers Squibb

Completed

Methotrexate - Inadequate Response Device Sub-Study (MTX-IR)

Rheumatoid Arthritis (RA)
University of Sao Paulo

Completed

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

Psychomotor Agitation

Brazil
Bristol-Myers Squibb

Completed

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Rheumatoid Arthritis

United States
Astellas Pharma Inc
Perseid Therapeutics LLC

Completed

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Withdrawn

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Melanoma

United States
Manhattan Psychiatric Center
Pfizer

Completed

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
Bristol-Myers Squibb

Completed

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis
Bristol-Myers Squibb

Completed

A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate

Rheumatoid Arthritis

Japan
Bristol-Myers Squibb

Completed

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Bristol-Myers Squibb

Completed

Comparability DE vs CD-CHO1

Healthy Subjects

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Bristol-Myers Squibb

Completed

Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Bristol-Myers Squibb

Completed

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

Melanoma

United States
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

United States
Bristol-Myers Squibb

Completed

The Study of Abatacept in Combination With Etanercept

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Rheumatoid Arthritis

Korea, Republic of, United States, Spain, Puerto Rico, Belgium, Australia, Canada, Mexico, France, Germany, Netherlands, Russian Federation, South Africa, United Kingdom, Brazil, Czech Republic, Italy, Poland
Bristol-Myers Squibb

Terminated

A Study of Abatacept in Patients With Active Crohn's Disease

Crohn's Disease

Australia, India, United States, Canada, Brazil, Mexico, Puerto Rico, Switzerland, Italy, Belgium, Netherlands, Denmark, France, Germany, South Africa, Czech Republic, Poland
Shriners Hospitals for Children
United Cerebral Palsy Foundation

Completed

The Effect of Botox on Children With Cerebral Palsy

Cerebral Palsy

United States
Bristol-Myers Squibb

Completed

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Bristol-Myers Squibb

Completed

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection (MDX1106-02)

Hepatitis C

United States
Bristol-Myers Squibb
Medarex

Completed

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

France, United States, Australia, Belgium, Germany, South Africa, Canada, Brazil, Czech Republic, Hungary
Charite University, Berlin, Germany
Bristol-Myers Squibb

Unknown

Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis (Aba-AS-01)

Ankylosing Spondylitis

Germany

Search clinical trials for: checkpoint

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations